EveryClinicalTrial, New Clinical Trial Registration Service
ECT is comprised of two primary services, Protocol+ for the registration of trials and Results Services for the publications of trial results.
EveryClinicalTrial (ECT), a service to address the registration and trial results requirements of ClinicalTrials.gov, is now available. ECT is comprised of two primary services, Protocol+ for the registration of trials and Results Services for the publications of trial results, and takes advantage of the company’s translational tools that offer efficiencies for uploading protocols to the site. The company predicts the service will be beneficial for all sponsors and institutions, but for those who only have a few trials a year, it offers a low-cost solution for a convoluted process. ECT Founder Colin Miller is formerly with BioClinica.
Read the full release.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
